Life Sciences

Featured thought leadership

• 

  The Connected Supply Chain

  The Future of the Life Sciences Supply Chain Series: Issue No. 1

• 

  Align your Stars

  How Medicare Advantage plans can navigate the changing landscape of Star ratings

• 

  Health Equity

  Doing good and doing well in life sciences

• 

  Effects of the IRA on the pharmaceutical industry

  A practical guide for pharmaceutical companies

• 

  CMS Announces Model Concepts to Reduce Prescription Drug Costs

  Model Concepts Provide Glimpse of What May be Ahead for Drug Pricing

• 

  Inflation Reduction Act: Part D Benefit Reforms: Impacts on Pharmaceutical Manufacturers, Plans, and Patients

  Part D Changes Likely to Impact Stakeholder Financial Incentives and Behavior

• 

  The Dawn of Precision Medicine in Neurodegenerative Diseases

  We are on the precipice of Precision Medicine in neurodegenerative diseases (NDDs)

• 

  Accelerated Approval Reforms in 2023 Omnibus

  Accelerated Approval Reforms Will Impact Drug Sponsors and FDA

• 

  KPMG 2023 Healthcare and Life Sciences Investment Outlook

  Our 2023 Healthcare and Life Sciences Investment Outlook finds turbulence, and opportunity, in this post-pandemic marketplace.

• 

  Maximizing the potential of your generic portfolio strategy

  The Inflation Reduction Act may usher in a new era of growth for generics manufacturers.

• 

  Spatial omics – microenvironments in full resolution

  KPMG perspective on this innovative technology

• 

  Shifting from compliance to quality

  Taking steps toward adopting computer software assurance (CSA) in life sciences

• 

  Biopharma Services Industry Update - November 2022

  Read more about M&A trends and activity in this sector

• 

  Transfer Pricing Considerations in the Age of Precision Medicine

  Disruption caused by chimeric antigen receptor T-cell (CAR T) therapy, a type of cell and gene therapy, to exploring standard business models in the life sciences industry.

• 

  KPMG life sciences technology insights report

  KPMG reports on the state of life sciences industry digital transformation, automation, artificial intelligence, and machine learning

• 

  Inflation Reduction Act impact on biopharma portfolio strategies

  An examination of potential implications for how drug manufacturers manage their portfolios in the wake of the Inflation Reduction Act

• 

  Life Sciences in a Time of Stress

  A reckoning in the aftermath of COVID

• 

  FCPA and anti-corruption strategies for the life sciences industry

  Mini-Roundtable

• 

  Deglobalization: the move to a better world order

  At a recent WSJ Future of Health forum, Ash Shehata, National Healthcare and Life Sciences lead spoke about Deglobalization.

• 

  Life Sciences: KPMG 2022 Fraud Outlook

  A triple threat across the Americas

• 

  Inflation Reduction Act: Healthcare provisions and impacts

  IRA will significantly impact prescription costs and insurance coverage for millions of Americans

• 

  Biopharma deal trends outlook for 2022

  Deal strategies will focus on risk mitigation, accelerated development, or risk sharing (licensing, partnerships, R&D collaborations).

• 

  In vitro diagnostics deal making

  Smaller Deals, More Partnerships, and Continued Innovation in 2022.

• 

  Liquid Biopsy – What’s real and what’s hype?

  KPMG perspective on this innovative technology

• 

  Psychedelic drugs: A market poised for takeoff

  With success in clinical trials for a range of mental disorders, psychedelics may soon move to the medical mainstream.

• 

  503B outsourcing facilities and pharma manufacturers

  Why the growth of 503Bs may be an opportunity for traditional pharma

• 

  FDA's Accelerated Approval Program: Accelerated Pathway for Reform?

  Reforms to FDA Accelerated Approval Program could include new confirmatory study requirements.

• 

  Pharma leaders collaborate on supply-chain security framework

  KPMG spearheaded a cross-institutional team of pharma supply-chain leaders to develop a proprietary cybersecurity framework.

• 

  2022 Healthcare and Life Sciences Investment Outlook

  Our 2022 Healthcare and Life Sciences Investment Outlook offers a look into industry innovations with the greatest investor interest.

• 

  Managing life sciences channel partners

  Improving distributor monitoring and compliance in an increasingly complex global life sciences market.

• 

  KPMG Life Sciences

  Experience in cell & gene therapies.

• 

  Research & Development Performance

  How to spot leaders vs. laggards.

• 

  The AI-enabled digital twin for life sciences

  An Artificial Intelligence (AI) enabled digital twin is a state-of-the-art simulation of a complex real-world system, enhancing predictive AI.

• 

  Thriving in an AI World: Life Sciences insights

  Life sciences companies have turned a corner in the wake of COVID-19 and are now looking toward a smarter, faster future.

• 

  ESG reporting – a new opportunity for CAOs

  How Chief Accounting Officers can lean into the challenge to enhance their strategic roles.

• 

  “One-and-done” gene therapies

  A near-term niche?

• 

  Managing risk and compliance in your SAP S/4HANA journey

  Life sciences companies face unique governance, risks and compliance challenges when implementing SAP S/4HANA technology.

• 

  Getting integration right in biotech acquisitions

  It takes a delicate balance of control and freedom to pursue innovation.

• 

  2021 Healthcare and Life Sciences Investment Outlook

  Provides insights on how the political and regulatory environment, and market factors may impact investment decisions.

• 

  Most Favored Nation Drug Pricing Model final rule

  On November 20, 2020, the Centers for Medicare and Medicaid Services announced the Most Favored Nation Drug Pricing Model.

• 

  Generics 2030: Three strategies to curb the downward spiral

  By 2030, generics manufacturers will need to shift from the status quo and explore one of three avenues for change.

• 

  Health Plan Transparency in Coverage Final Rule

  HHS, Department of Labor, and Treasury finalized price transparency requirements for health plans set to take effect beginning in 2022.

• 

  FDA final rule and guidance on importation of prescription drugs

  FDA finalized a rule and guidance allowing states to submit prescription drug importation proposals and manufacturers to re-label drugs for importation.

• 

  Executive order on ‘Most-Favored-Nation’ drug pricing

  An Executive Order directs HHS rulemaking for “most favored nations” pricing for Medicare Part B and D drugs.

• 

  Executive orders on prescription drug costs

  Four Executive Orders (EO) described as action to deliver lower prescription drug prices to American Patients.

• 

  The clinical trial conundrum

  Failing to resume clinical trials could present as many risks to certain patients as COVID-19.

• 

  Re-launching elective procedures

  An opportunity for medical device companies to shape their future customer base.

• 

  KPMG Digital Lighthouse: Powering Life Sciences with advanced analytics

  The Life Sciences Industry is moving towards a dramatically different future based on a number of market drivers.

• 

  Diagnostics: Ramp-up of testing for COVID-19 & beyond

  Private labs seeking to restructure or build to deploy COVID-19 testing operations can benefit from KPMG’s rapid start-up approach.

• 

  Restarting America – Practical Guide for Employers

  For businesses making decisions about when and how to reopen their businesses, here is a practical guide to key considerations.

• 

  Paycheck Protection Program and Health Care Enhancement Act

  Implications for Healthcare providers.

• 

  Part D senior savings model for insulin coverage

  CMS just announced alternative Part D options that lower seniors’ cost-sharing for insulin, according to the attached issue brief.

• 

  Coronavirus Aid, Relief, and Economic Security (CARES) Act

  Economic support and stimulus bill.

• 

  2020 healthcare and life sciences investment outlook

  Analysis of the 2020 KPMG Healthcare and Life Sciences Investment Outlook survey sheds light on how the investment landscape will be impacted by influential disruptors, evolving market trends, and policy/regulatory developments.

• 

  The Race to EU MDR Compliance Continues

  Despite progress, companies are still facing many questions.

• 

  Quality 2030

  Forward-thinking Life Sciences CXOs will transform Quality from a cost center to a value creator.

• 

  Embracing transparency

  Instead of viewing calls for transparency as a burden, pharmaceutical companies can take steps to turn pricing reform to their advantage.

• 

  Prescription drug rebates

  Proposed safe harbor changes open for comment.

• 

  Driving value from genomics in Life Sciences

  Rising to the data challenge.

• 

  R&D 2030

  Reinvent innovation and become an R&D front-runner by 2030.

• 

  Opportunities in an evolving market

  2019 Health Care & Life Sciences Investment Outlook.

• 

  Digital transformation in regulatory affairs

  Unlocking value for life sciences organizations.

• 

  The race to EU MDR compliance

  KPMG/RAPS survey illustrates the ground medical device companies still have to cover.

• 

  Digital health and disruption in diabetes

  Identifying opportunities for life sciences manufacturers.

• 

  Insider threat in life sciences

  2018 Program benchmark report.

• 

  Future of finance: Finance disrupted

  Innovation in the life sciences finance function.

• 

  The disruption challenge

  As new entrants and cross-sector models abound, which direction should healthcare organizations turn?

• 

  Demystifying blockchain for life sciences

  Blockchain could be a key to interoperability and privacy.

• 

  Revenue for the life sciences industry

  New standard. New challenges.

• 

  2018 Health care & life sciences investment outlook

  Healthcare and life sciences will face continued disruption in 2018 as new technologies, economic pressures and consumer/patient demands change the industry.